Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 16 citing articles:

What have we learned about TP53-mutated acute myeloid leukemia?
Moazzam Shahzad, Muhammad Kashif Amin, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia
Yu Zhang, Zhao Yin, Zurong Yao, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
TP53‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges
Bipin Ghimire, Markie Zimmer, Vijayalakshmi Donthireddy
European Journal Of Haematology (2025)
Open Access
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Mithun Vinod Shah, Daniel A. Arber, Devendra Hiwase
American Journal of Hematology (2025)
Open Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Amandeep Kaur, Alexandra E. Rojek, Emily Symes, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
Francis LeBlanc, Erin H. Breese, Karen Burns, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 1055-1066
Open Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia
Shyam A. Patel
Leukemia (2024)
Closed Access | Times Cited: 2
Novel insights and therapeutic approaches in secondary AML
Giovanni Marconi, Michela Rondoni, Beatrice Anna Zannetti, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
A Line in Shifting Sand: Can We Define and Target TP53 Mutated MDS?
Sarah Skuli, Andrew Matthews, Martin Carroll, et al.
Seminars in Hematology (2024)
Closed Access | Times Cited: 1
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.
Talha Badar, Keith L. Knutson, James M. Foran, et al.
Blood Advances (2024)
Open Access | Times Cited: 1
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Ansh Mehta, Marina Konopleva
Hematology (2024) Vol. 2024, Iss. 1, pp. 326-334
Closed Access | Times Cited: 1
Real World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid Neoplasms
Amandeep Kaur, Alexandra E. Rojek, Emily Symes, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Transplant or no transplant for TP53 mutated AML
Talha Badar, Moazzam Shahzad, Ehab Atallah, et al.
Oncotarget (2024) Vol. 15, Iss. 1, pp. 674-676
Open Access
Somatic co‐alteration signatures are prognostic in high‐grade TP53‐mutated myeloid neoplasms
Emily Symes, Peng Wang, Payal Sojitra, et al.
British Journal of Haematology (2024)
Open Access
Page 1

Scroll to top